Search
for
Sort by
Research 211–240 of 1000+
- Targeted immunotherapy for hair regrowth and regeneration
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- An Updated in the Management of Alopecia Areata
- Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs
- Skin Biology and Ageing
- BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
- T <sub>H</sub> 1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
- Human Leukocyte Antigen Class II Alleles Are Associated with Risk of Alopecia Areata
- Brave New World
- Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
- Nail Brace Application
- Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
- Folliculin: A surprising molecular brake in the human hair follicle
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program
- Herpes Zoster y COVID 19, coexistencia en un paciente no inmunodeprimido. Reporte de un caso y breve revisión a propósito del mismo.
- Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
- Fifty-six years of plastic surgery
- Foxn1 promotes keratinocyte differentiation by regulating the activity of protein kinase C
- Wear characteristics of epoxy based hybrid composites reinforced with short hair fibers and glass micro spheres
- Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
- Baricitinib regrows hair in adolescents with alopecia areata
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
- The Hair Follicle as an Estrogen Target and Source
- 715 Hunting the hair cycle clock (HCC): Evidence that mitochondrially localized MPZL3 is a key HCC element in murine and human hair follicles